PROGRAM OVERVIEW Can you ID OIC? Find solutions to detect, diagnose, and manage opioid-induced constipation (OIC) sooner in your patients with chronic, non-cancer pain.This CME case-based activity features:
- Tools to screen patients and talk to them about OIC
- Criteria and symptoms that can be used to better assess and diagnose OIC
LEARNING OBJECTIVES Upon completion of this educational activity, participants should be able to:
- Incorporate into practice, communication strategies to improve the screening of patients for OIC
- Evaluate patients’ symptoms and clinical history to guide OIC diagnosis
FACULTY Bill H. McCarberg, MD Founder, Chronic Pain Management Program
Kaiser Permanente San Diego (retired)
Adjunct Assistant Clinical Professor
University of California, San Diego
San Diego, CA
DISCLOSURES STATEMENTS In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.
Bill H. McCarberg, MD Speakers Bureau: Millennium Pharmaceuticals, Inc
Consultant/Advisory Board: Collegium Pharmaceutical; Iroko Pharmaceuticals, LLC;
Millennium Pharmaceuticals, Inc; Pfizer Inc; Zogenix, Inc
Stockholder: BioSpecifics Technologies Corp; Johnson & Johnson; Nektar
Therapeutics; PDL BioPharma, Inc (formerly Protein Design Labs, Inc)
In order to resolve conflict of interest, presentations of this activity were peer reviewed by an independent reviewer. The reviewer has no relationship with a commercial interest. The resulting certified activity was found to provide educational content that is current, evidence based, and commercially balanced.
Independent Reviewer Bernard M. Abrams, MD Medical Director
Dannemiller
San Antonio, TX
Clinical Professor of Neurology
University of Missouri School of Medicine at Kansas City
Kansas City, MO
Nothing to disclose with regard to commercial support
Educational Planning Committee Dannemiller Gordon Ringler
Nothing to disclose with regard to commercial support
Spire Learning Jeanne Prater Shareholder (Spouse/Partner): Johnson & Johnson
Employee (Spouse/Partner): Novo Nordisk
Jaime Symowicz, PhD
Nothing to disclose with regard to commercial support
DISCLAIMER The content and views presented in this educational activity are those of the presenter and do not necessarily reflect those of Dannemiller, Takeda Pharmaceuticals International, Inc., U.S. Region, Sucampo, or Spire Learning. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
OFF-LABEL STATEMENT The faculty author does not intend to discuss non–FDA-approved or investigational use of any commercial products in this presentation. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
LEVELS OF EVIDENCE Levels of evidence are provided for any patient care recommendations made during this presentation.
Level A (randomized controlled trial/meta-analysis): High-quality, randomized controlled trial (RCT) that considers all important outcomes. High-quality meta-analysis (quantitative systematic review) using comprehensive search strategies
Level B (other evidence): A well-designed, nonrandomized clinical trial. A nonquantitative systematic review with appropriate search strategies and well-substantiated conclusions. Includes lower-quality RCTs, clinical cohort studies, and case-controlled studies with nonbiased selection of study participants and consistent findings. Other evidence, such as high-quality, historical, uncontrolled studies, or well-designed epidemiologic studies with compelling findings, is also included
Level C (consensus/expert opinion): Consensus viewpoint or expert opinion.Each rating is applied to a single reference in the presentation, not the entire body of evidence on the topic
FACULTY BIOGRAPHY Bill H. McCarberg, MD Bill H. McCarberg, MD, is Founder of the Chronic Pain Management Program for Kaiser Permanente (retired) in San Diego, California. He is also an Adjunct Assistant Clinical Professor at the University of California, San Diego School of Medicine. Dr McCarberg is currently working with Neighborhood Healthcare in Escondido, California. He received his medical degree from Northwestern University Feinberg School of Medicine in Chicago, Illinois, and he completed his medical internship and residency in family medicine at Highland Hospital in Rochester, New York.
Dr McCarberg has given more than 500 presentations on pain management topics and is the author or coauthor of 115 articles, book chapters, and books. He is board certified by the American Board of Pain Medicine and the American Board of Family Practice with additional certification in geriatric medicine. He is also treasurer of the American Board of Pain Medicine and president of the Western Pain Society. In addition, Dr McCarberg is a member of the American Academy of Family Physicians, the American Academy of Pain Medicine, the American Pain Society, and the International Association for the Study of Pain. He is the recipient of several awards, including the Shilling Compassionate Care Award from Kaiser Permanente and the Elizabeth Narcessian award for leaders in the field of pain education from the American Pain Society. In 2008, he was named Ambassador of the Year by the National Pain Foundation. Dr McCarberg was consistently rated in the top 10% by Member Appraisal of Physician/Provider Services at Kaiser Permanente from 1998 to 2011.